Affimed (AFMD) Prices 12M Share Common Offering at $2.50/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. SPY
9. FIX
10. NDAQ

Go back to Affimed (AFMD) Prices 12M Share Common Offering at $2.50/Sh

Affimed (AFMD) Reports FDA Clearance of IND to Begin First-in-Human Phase 1/2a Study of AFM24 for Treatment of EGFR-Expressing Cancers

November 8, 2019 5:54 AM EST

Affimed N.V. (NASDAQ: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that its Investigational New Drug application (IND) has cleared the required 30-day review by the U.S. Food and Drug Administration (FDA) and is in effect for a Phase 1/2a clinical trial of AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager, in patients with advanced cancers known to express EGFR.

The IND clearance of AFM24 enables us to proceed... More

Affimed (AFMD) Announces Proposed Public Offering of Common Shares

November 7, 2019 4:13 PM EST

Affimed N.V. (Affimed or the Company) (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has commenced an underwritten public offering of its common shares. The Company expects to grant the... More